

Tissue Factor Pathway Inhibitor in Patients with Coronary Heart Diseases

Thesis

Submitted for Partial Fulfillment of M.Sc. Degree
in Clinical and Chemical Pathology

By

Marwa Othman Abd El Moteleb

M.B., B.Ch

Ain Shams University

Supervised by

Professor/ Afaf Abd El Aziz Abd El ghafar

Professor of Clinical and Chemical pathology

Faculty of Medicine-Ain Shams University

Professor / Manal A. Shams Eldin El Telbany

Professor of Clinical and Chemical Pathology

Faculty of Medicine-Ain Shams University

Doctor / Abeer Atia Saad

Lecturer of Clinical and Chemical Pathology

Faculty of Medicine-Ain Shams University

Faculty of Medicine

Ain Shams University

2009

Acknowledgment

In the name of Allah, the all merciful the ever merciful. Thank you my God for showing me the way, giving me the strength, and helping me to finish this work. I beg you to forgive my mistakes you are the all forgiver and the ever merciful.

*I'm also deeply indebted to **Prof. Dr. Afaf Abd EL Aziz Abd EL Ghafar**, Professor of Clinical and Chemical pathology, Faculty of Medicine, Ain Shams University, for her meticulous extensive revision of this work, her kind encouragement and support, and her straight personality that helped me a lot in writing this work,*

*I'm deeply indebted to **Prof. Dr. Manal A. Shams Eldin EL Telbany**, Professor of Clinical and Chemical pathology, Faculty of Medicine, Ain Shams University, for her great effort with me and her meticulous and serious personality that inspired me throughout this work,*

*It's an honour to express my deep appreciation and sincere thanks to **Dr. Abeer Atia Saad**, lecturer of Clinical and Chemical pathology, Faculty of Medicine, Ain Shams University, for her great effort, guidance, valuable advice and enthusiastic encouragement which really enabled the accomplishment of this work,*

Finally, I'm most indebted to my family for their great support, endless giving, and their kind merciful souls that bless my heart and wash my pains out even if I have nothing to give in return.

List of Contents

| | <i>Page</i> |
|---|-------------|
| Introduction and Aim of the work | 1-3 |
| Review of literature: | |
| Chapter 1: | |
| - Pathogenesis of coronary heart disease | 4 |
| - Pathology of coronary heart disease | 7 |
| - CHD presentations | 10 |
| - Coronary heart disease risk | 16 |
| Chapter 2: | |
| - Coagulation cascade | 42 |
| - TFPI levels in the normal population | 44 |
| - Structure and some physiochemical properties of TFPI | 44 |
| - TFPI production | 47 |
| - Methods for TFPI determination | 47 |
| - Variables that could potentially influence TFPI activity | 51 |
| - Role of TFPI in various disease states | 54 |
| - Potential therapeutic applications of TFPI | 60 |



List of Contents (Cont.)

| | <i>Page</i> |
|-------------------------------------|-------------|
| Subjects and methods | 62 |
| Results | 72 |
| Discussion | 91 |
| Summary and Conclusion | 98 |
| Recommendations | 101 |
| References | 102 |
| Arabic summary | — |



List of Tables

| <i>Table</i> | <i>Page</i> |
|---|-------------|
| Table (1): Properties of biomarkers of myocardial necrosis | 17 |
| Table (2): Comparative analysis of the studied parameters among patient groups versus control..... | 79 |
| Table (3): Comparative analysis of the studied parameters among patient groups | 80 |
| Table (4): The TFPI plasma levels among studied subjects | 81 |
| Table (5): Correlation between TFPI among studied groups | 81 |
| Table (6): Association between TFPI Plasma levels and other studied risk factors | 82 |
| Table (7): Impact of TFPI Plasma level on CHD severity among studied patients | 83 |
| Table (8): Descriptive data of myocardial infarction patients (Group I) | 84 |

List of Tables (Cont.)

| <i>Table</i> | <i>Page</i> |
|--|-------------|
| Table (9): Descriptive data of unstable angina patients (Group II) | 85 |
| Table (10): Descriptive data of stable angina patients (Group III) | 86 |
| Table (11): Descriptive data of control group | 87 |

List of Figures

| <i>Figure</i> | <i>Page</i> |
|---|-------------|
| Figure (1): Participation of inflammation in all stages of atherosclerosis | 7 |
| Figure (2): Microscopic findings of normal coronary artery | 7 |
| Figure (3): High magnification of the atheroma shows numerous foam cells and numerous dark blue inflammatory cells scattered within the atheroma | 8 |
| Figure (4): Severe degree of narrowing in coronary artery | 9 |
| Figure (5): Cascade model of coagulation | 43 |
| Figure (6): Model of TFPI showing the kunitz-type domains and the positively and negatively charged amino acid groups | 46 |
| Figure (7): Comparison between patient groups and control regarding BMI | 88 |
| Figure (8): Comparison between patient groups and control regarding Diabetes mellitus | 88 |



List of Figures (Cont.)

| <i>Figure</i> | <i>Page</i> |
|---|-------------|
| Figure (9): Comparison between patient groups and control regarding Hypertension | 89 |
| Figure (10): The TFPI levels among studied subjects | 89 |
| Figure (11): Receiver operating characteristic (ROC) curve to define the best cutoff to predict coronary heart disease (Prognostic factor) | 90 |



List of Abbreviations

- 2hrPPG**.....2-hours postprandial plasma glucose.
- ACS**Acute coronary syndrome.
- AMI**Acute myocardial infarction.
- Apo B**.....Apolipoprotein B.
- APS**Antiphospholipid syndrome.
- BMI**.....Body mass index.
- CHD**.....Coronary heart disease.
- CK-MB**.....Creatinine kinase muscle-brain fraction.
- CMV**Cytomegalovirus.
- CRP**C-reactive protein.
- cTnI**Cardiac troponin which binds to actin and inhibits actin-myosin interactions.
- cTnT**Cardiac troponin which binds to tropomyosin.
- DM**.....Diabetes mellitus.
- DNA**.....Deoxyribonucleic acid.
- DPT**.....Diluted prothrombin time.
- ECG**.....Electrocardiogram.
- ECs**.....Endothelial cells.
- EPI**.....Extrinsic pathway inhibitor.
- HbA1c**.....Glycated haemoglobin.
- Hcy**.....Amino acid homocysteine.



| | |
|---------------------|---|
| HDL | H igh-density lipoprotein. |
| HLE | H uman leukocyte elastase. |
| HMG-COA .. | H ydroxy-methylglutaryl coenzyme A. |
| hs-CRP | H ighly sensitive C-reactive protein. |
| HTN | H ypertension. |
| HUVECs | H uman umbilical vein endothelial cell. |
| ICAM-1 | I ntercellular adhesion molecule-1. |
| IDL | I ntermediate density lipoprotein. |
| IGT | I mpaired glucose tolerance. |
| IHD | I schaemic heart disease. |
| IL-1 | I nterleukin-1. |
| IL-6 | I nterleukin-6. |
| LACI | L ipoprotein-associated coagulation inhibitor. |
| LDL | L ow density lipoprotein. |
| LDL | L ow density lipoprotein. |
| LP (a) | L ipoprotein (a). |
| MI | M yocardial infarction. |
| mRNA | M essenger ribonucleic acid. |
| NCEP | N ational Cholesterol Education Program. |
| NSTEMI | N on-ST elevation myocardial infarction. |
| PAI-1 | P lasminogen activator inhibitor-1. |
| PAPS | P rimary Antiphospholipid syndrome. |
| PECAM1 | P latelet endothelial cell adhesion molecule. |



List of Abbreviations

- r TFPI**.....**R**ecombinant tissue factor pathway inhibitor.
- SMCs****S**mooth muscle cells.
- STEMI**.....**S**T elevation myocardial infarction.
- TF**.....**T**issue factor.
- TFI**.....**T**issue factor inhibitor.
- TFPI**.....**T**issue factor pathway inhibitor.
- TGF****T**umor growth factor.
- TNF- α** **T**umor necrosis factor- α .
- t-PA**.....**T**issue plasminogen activator.
- UA**.....**U**nstable Angina.
- VCAM-1**.....**V**ascular cell adhesion molecule-1.
- VLDL**.....**V**ery low density lipoprotein.
- WHO****W**orld Health Organization.



Introduction

Coronary heart disease is a leading cause for morbidity and mortality in many countries world wide. Despite the search for novel risk factors, established ones still play a major role. These are the dyslipidaemias, hypertension, cigarette smoking, diabetes, obesity and physical inactivity (**Lee et al., 2001**). Haemostasis plays an important role in the development of cardiac complications (**Lisowski et al., 2004**).

One of the most frequent and serious complications associated with cardiovascular disease is thrombosis, possibly arising from increased platelet activation and/or loss of the regulation of coagulation and fibrinolysis (**Ross, 2007**).

Tissue factor is the main physiological initiator of blood coagulation (**Vieira et al., 2007**). It binds and acts as an essential cofactor for active factor VII (FVIIa) (**Soejima et al., 2000**).

Tissue factor pathway inhibitor is the main physiological inhibitor of tissue factor induced coagulation, it is mainly synthesized by endothelial cells (**Bajaj et al., 2001**). It has a dual inhibitory function, it inhibits the complex factor VIIa/tissue factor and directly inhibits factor Xa by binding at or near its active site (**Li et al., 2001**).



The presence of tissue factor pathway inhibitor in atherosclerotic plaques is associated with reduced tissue factor activity and its local administration is highly effective in reducing arterial thrombosis in atherosclerotic lesions (**Badimon et al., 2003**).

Blood clotting activation has been demonstrated in patients with ischaemic heart disease (**Theroux et al., 2000**) and a key role of tissue factor expressed by monocytes in triggering thrombin generation has been documented (**Neri Serneri et al., 2001**).

Moreover; in ischaemic heart disease patients; tissue factor pathway inhibitor activity was found to be moderately higher (**Sandset et al., 2002**), particularly in hyperlipidemics.



Aim of the Work

- 1- To measure the plasma level of tissue factor pathway inhibitor in patients with acute myocardial infarction, unstable angina and stable angina pectoris and compare it with those found in normal healthy subjects.
- 2- To evaluate the role of tissue factor pathway inhibitor as a risk factor for coronary heart disease.



CORONARY HEART DISEASE

Coronary heart disease (CHD) is the leading cause of death and disability in both men and women. Its presentation varies from chronic CHD to acute coronary syndrome (ACS) that includes unstable angina and myocardial infarction (Nguyen and McLanghlin, 2002).

Understanding the pathophysiology that leads to CHD and identifying the risk factors are crucial steps for efforts to prevent this disease (Wilson et al., 2002 and Pischon et al., 2007).

According to the Ministry of Health (MOH) and World Health Organization (WHO) Regional office report, there is an increased prevalence of coronary heart disease in Egypt which is responsible for about 47% of all deaths among Egyptians (Ibrahim et al., 2009).

I) PATHOGENESIS of CORONARY HEART DISEASE:

The underlying processes that lead to atheroma formation and coronary thrombosis are complex and involve multiple interrelated systems that regulate vasoactivity, adhesion molecules and their ligands, lipid metabolism, coagulation and fibrinolytic pathways (Lane and Grant, 2000).